<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499367</url>
  </required_header>
  <id_info>
    <org_study_id>N15TON</org_study_id>
    <nct_id>NCT02499367</nct_id>
  </id_info>
  <brief_title>Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients</brief_title>
  <acronym>TONIC</acronym>
  <official_title>Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients: TONIC-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center non-blinded randomized non-comparative phase II trial. The first
      stage of the trial consists of five arms ( with induction treatment followed by nivolumab, 1
      with no induction treatment before nivolumab).

      For the second stage, the number of arms will be reduced based on the results obtained in the
      first stage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Triple negative breast cancer (TNBC) patients have a relatively high relapse rate and upon
      relapse the median overall survival is less than a year. No targeted therapies are currently
      available for this subgroup. Compared to other breast cancer subtypes, the percentage of
      tumor-infiltrating lymphocytes (TILs) is significantly higher in TNBC. Given the durable
      responses induced by the immune checkpoint inhibitor nivolumab in other advanced solid
      cancers, immunotherapeutic approaches, such as blockade of PD-1 by nivolumab may be the key
      to treat TNBC. Moreover, since classical anticancer agents can stimulate immune effector
      cells, the investigators hypothesize that short-term induction treatment with radiation,
      doxorubicin, cyclophosphamide or cisplatin induces an anticancer immune response resulting in
      synergistic activity with nivolumab.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>assessed monthly until progression; median 12 months</time_frame>
    <description>Time from randomization todate of first tumor progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>At 12 weeks and 6 months</time_frame>
    <description>complete response or partial response at 12 weeks and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>At 6 months</time_frame>
    <description>Beneficial response (complete response, partial response or stable disease) at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of all study regimens</measure>
    <time_frame>assessed until 100 days after of treatment end</time_frame>
    <description>adverse events will be graded according to NCI Common Toxicity Criteria v 4.0</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy on metastatic lesion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15mg flat dose, once weekly for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metronomic schedule, 50mg daily orally for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40mg/m2, weekly for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No induction treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>nivolumab 3 mg/kg, every 2 weeks after induction treatment</description>
    <arm_group_label>Radiation therapy</arm_group_label>
    <arm_group_label>Low dose doxorubicin</arm_group_label>
    <arm_group_label>Cyclophosphamide</arm_group_label>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_label>No induction treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>20 Gy to metastatic lesion</description>
    <arm_group_label>Radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose doxorubicin</intervention_name>
    <description>15 mg flat dose, once weekly for 2 weeks</description>
    <arm_group_label>Low dose doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>metronomic schedule, 50 mg daily orally for 2 weeks</description>
    <arm_group_label>Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>40 mg/m2, weekly for 2 weeks</description>
    <arm_group_label>Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic triple negative breast cancer with confirmation of Estrogen Receptor (ER)
             and HER2 negativity on a histological biopsy of a metastatic lesion

          -  18 years or older

          -  Metastatic lesion accessible for histological biopsy (Mandatory biopsies:
             pre-induction treatment, post-induction treatment, 6-weeks. Optional biopsies:
             12-weeks, at progression, of irradiated site). The pre-induction treatment biopsy has
             to contain sufficient tumor content (â‰¥100 tumor cells); subjects with samples that
             have insufficient tumor content will require re-biopsy prior to induction treatment.
             Interval between last treatment and pre-induction biopsy has to be at least 14 days

          -  One, two or three line(s) of chemotherapy for metastatic disease and with progression
             of disease on last treatment regimen

          -  Evaluable disease according to RECIST 1.1

          -  Metastatic lesion accessible for radiation with 1x20 Gray or 3x8 Gray

          -  Subjects with brain metastases are eligible if these are not symptomatic. Subjects who
             received prior treatment for brain metastases should be free of progression on
             magnetic resonance imaging (MRI) for at least 4 weeks after treatment is completed and
             prior to first dose of study drug administration. There must also be no requirement
             for immunosuppressive doses of systemic corticosteroids (&gt; 10 mg/day prednisone
             equivalents) for at least 2 weeks prior to study drug administration.

          -  WHO performance status of 0 or 1

          -  Adequate bone marrow function

          -  Adequate hepatic function

          -  Adequate renal function

          -  Signed written informed consent

        Exclusion Criteria:

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris.

          -  known history of leptomeningeal disease localization

          -  history of having received other anticancer therapies within 2 weeks of start of the
             study drug

          -  history of immunodeficiency, autoimmune disease, conditions requiring
             immunosuppression (&gt;10 mgl daily prednisone equivalents) or chronic infections.

          -  prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody

          -  live vaccine within 30 days of planned start of study therapy.

          -  active other cancer

          -  positive test for hepatitis B surface virus surface antigen (HBsAg) or hepatitis

          -  history of uncontrolled serious medical or psychiatric illness

          -  any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule

          -  current pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen Kok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marleen Kok, MD</last_name>
    <phone>+3120512</phone>
    <phone_ext>7901</phone_ext>
    <email>m.kok@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid AM Mandjes, MSc</last_name>
    <phone>+3120512</phone>
    <phone_ext>2667</phone_ext>
    <email>i.mandjes@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen Kok, MD</last_name>
      <phone>+3120512</phone>
      <phone_ext>7901</phone_ext>
      <email>m.kok@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ingrid AM Mandjes, MSc</last_name>
      <phone>+3120512</phone>
      <phone_ext>2667</phone_ext>
      <email>i.mandjes@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Marleen kok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>triple negative</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

